| abstract |
Breton tyrosine kinase (Btk) inhibitor 1-((R) -3- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-1-yl) piperidine- Pharmaceutical formulations of 1-yl) prop-2-en-1-one are described herein. Also, Btk inhibitors are used alone or in combination with other therapeutic agents for the treatment of cancer and inflammatory diseases or conditions, including autoimmune diseases or conditions, heterogeneous immune diseases or conditions, lymphomas. A method is also disclosed. [Selection] Figure 1 |